NeuroVive's pipeline also includes a cyclophilin inhibitor for stroke and drug candidates that act on mitochondria to address energy regulation disorders.
NeuroVive´s shares are listed on the Swedish trading platform AktieTorget ( http://www.aktietorget.se). The AktieTorget market is focused on emerging, entrepreneurial businesses through an electronic trading system supplied by the OMX Nordic stock exchange in Stockholm, Sweden.
Media and investor relations contacts
NeuroVive Pharmaceutical: Mikael Bronnegard Email: firstname.lastname@example.org Phone No: +46 (0) 70 299 62 64Citigate Dewe Rogerson: Nina Enegren / David Dible Email: email@example.com Phone No: +44 207 282 1050 SOURCE NeuroVive